Cuantificación del antígeno de superficie del virus de la hepatitis B: implicaciones clínicas

Blumberg, 1965, A «new» antigen in leukemia sera, JAMA, 191, 541, 10.1001/jama.1965.03080070025007 Rotman Y, Brown AT, Hoofnagle JH. Evaluation of the patient with hepatitis B. Hepatology. 2009 (5 Suppl); 49:S22–27 Seeger, 2000, Hepatitis B virus biology, Microbiol Mol Biol Rev, 64, 51, 10.1128/MMBR.64.1.51-68.2000 Simon, 1988, Secreted hepatitis B surface antigen polypeptides are derived from transmembrane precursor, J Cell Biol, 107, 2163, 10.1083/jcb.107.6.2163 De Medina, 1988, The S promoter of HBV is regulated by positive and negative elements, Mol Cell Biol, 8, 2449, 10.1128/MCB.8.6.2449 Stibbe, 1983, Structural relationship between minor and major proteins of hepatitis B surface antigen, J Virol, 46, 626, 10.1128/JVI.46.2.626-628.1983 Heermann, 1984, Large surface proteins of HBV containing the Pre-s sequence, J Virol, 52, 396, 10.1128/JVI.52.2.396-402.1984 Dienes, 1990, Hepatic expression patterns of the large and middle hepatitis B surface proteins in viremic and non viremic chronic hepatitis B, Gastroenterology, 98, 1017, 10.1016/0016-5085(90)90028-Y Le Guillou, 2000, Evaluation of an enzyme-linked immunosorbent assay for detection and quantification of hepatitis B virus PreS1 envelope antigen in serum samples: comparison with two commercial assays for monitoring hepatitis B virus DNA, J Viral Hepat, 7, 387, 10.1046/j.1365-2893.2000.00248.x Wursthorn, 2011, Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum, J Clin Virol, 10.1016/j.jcv.2010.12.008 Lee, 2011, Quantification of HBsAg: Basic virology for clinical practice, World J Gastroenterol, 17, 283, 10.3748/wjg.v17.i3.283 Wiegand, 2008, A decline in hepatitis B virus surface antigen predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels, Antivir Ther, 13, 547, 10.1177/135965350801300402 Manesis, 2007, Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels, Antivir Ther, 12, 73, 10.1177/135965350701200107 Nguyen, 2009, The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B, Hepatol Int, 3 (Suppl 1), S5, 10.1007/s12072-009-9149-7 Wursthorn, 2006, Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B, Hepatology, 44, 675, 10.1002/hep.21282 Werle-Lapostolle, 2004, Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy, Gastroenterology, 126, 1750, 10.1053/j.gastro.2004.03.018 Perrillo, 2009, Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns, Hepatology, 49, 1063, 10.1002/hep.22932 Thompson, 2010, Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers, Hepatology, 51, 1933, 10.1002/hep.23571 Kimbi, 2005, Integration of hepatitis B virus DNA into chromosomal DNA during acute hepatitis B, World J Gastroenterol, 11, 6416, 10.3748/wjg.v11.i41.6416 Bill, 2004, Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration, Proc Natl Acad Sci USA, 101, 11135, 10.1073/pnas.0403925101 Nguyen, 2010, Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia, J Hepatol, 52, 508, 10.1016/j.jhep.2010.01.007 Jaroszewicz, 2010, Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective, J Hepatol, 52, 514, 10.1016/j.jhep.2010.01.014 Brunetto, 2010, Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers, Gastroenterology, 139, 483, 10.1053/j.gastro.2010.04.052 Brunetto, 2009, Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B, Hepatology, 49, 1141, 10.1002/hep.22760 Moucari, 2009, Early serum HBsAg drop:a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients, Hepatology, 49, 1151, 10.1002/hep.22744 Chen, 2009, Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peginterferon-alpha-2a, Antiviral Res, 81, 88, 10.1016/j.antiviral.2008.09.005 Rijckborst, 2010, Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels, Hepatology, 52, 454, 10.1002/hep.23722 Sonneveld, 2010, Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline, Hepatology, 52, 1251, 10.1002/hep.23844 Gane, 2010, HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment [Abstract], J Hepatol, 52, S388, 10.1016/S0168-8278(10)61007-0 Liaw, 2009, 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B, Gastroenterology, 136, 486, 10.1053/j.gastro.2008.10.026 Wursthorn, 2010, Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients, Hepatology, 52, 1611, 10.1002/hep.23905